Pfizer Cancer Drug Efficacy Triggers Early Phase III Trial Termination

Angiogenesis inhibitor SU11248 shows significant efficacy in Gleevec-resistant gastrointestinal stromal tumors; Pfizer plans NDA submission for GIST and renal cell carcinoma by end of 2005. A Phase III trial in second-line renal cell carcinoma is ongoing.